Across TCGA pan-cancer cohorts, ZPBP2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZPBP2 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher ZPBP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZPBP2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

CESC, LUSC, and SKCM are the cancer types where ZPBP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.404	0.878	<.001	42	view →
LUSC	DFS	Median	II,III,IV	0.079	0.750	<.001	24	view →
SKCM	DFS	Median	II,III,IV	0.902	0.544	.028	7	view →
UCEC	DFS	Median	All	1.000	0.629	.024	6	view →
BLCA	OS	Median	II,III,IV	1.000	0.411	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ZPBP2 tumor-vs-normal RNA expression · all ZPBP2 data types